NICE's severity modifiers misalign with public preferences in England & Wales, prioritising health gains at lower disease ...

More collaborative initiatives are taking place among regulatory agencies, health technology assessment bodies and between ...

For the growing number of multi-indication medicines, challenges arise in assessing and paying for value across medicine indications with a uniform price (see our previous report and further ...

Ting (Tina) Wang is Associate Director, HTA Programme and Strategic Partnerships at the Centre for Innovation in Regulatory Science (CIRS). Tina leads CIRS’ work on HTA strategy and research as part ...

Bhaven N. Sampat is an economist by training, a Professor at the Department of Health Policy and Management at Columbia University, and a Research Associate at the National Bureau of Economic Research ...

Stuart Carroll is a senior health economist and epidemiologist with over 18 years of experience, specialising in infectious diseases and vaccines, market access, health technology appraisal, public ...

Should Health Technology Assessment Include the Bereavement Effect on Health-Related Quality of Life? What Difference Could It Make to Decisions About Life-Extending Treatments? Chris Skedgel ...

Ellie is on the fellowship programme with City University, studying Economic Evaluation in Healthcare. She has a BSc in Biochemistry from the University of Bath and worked in the pharmaceutical ...

Siva is chief analyst in the policy team, leading on projects covering NHS funding, finances, productivity and performance. Before joining the Fund in 2017, Siva was head of analysis at NHS Providers ...

Donna is Professor of Health Economics at the School of Health and Related Research at the University of Sheffield.